Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

James R. Hocker, Subrato J. Deb, Min Li, Megan R. Lerner, Stan A. Lightfoot, Aurelien A. Quillet, R. Jane Hanas, Matthew Reinersman, Jess L Thompson, Nicole T. Vu, Thomas C. Kupiec, Daniel J. Brackett, Marvin D. Peyton, Stephen M. Dubinett, Harold M. Burkhart, Russell G. Postier, Jay S. Hanas

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalCancer Investigation
DOIs
StateAccepted/In press - Sep 22 2017
Externally publishedYes

Keywords

  •  

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients'. Together they form a unique fingerprint.

Cite this